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 SUMMARY 
  Although a number of studies have been conducted on health production functions, little 
attention has been given to pharmaceuticals as a separate input into the production of health.  
Building upon existing published work, this paper uses an alternative specification and more 
recent data to estimate the effect of pharmaceutical expenditures on levels of health in the 
member countries of the Organization for Economic Cooperation and Development (OECD).  In 
a sample of developed countries, we found that pharmaceutical consumption, as measured by per 
capita drug expenditures, has a positive effect on life expectancy at advanced ages.  The 
marginal effect of pharmaceutical consumption is consistent with estimates that have been 
reported previously but appears to decline with increasing age.  Over the past few years, the 
substantial and disproportionate growth of pharmaceutical expenditures for public and private 
payers in the U.S. has led to calls for regulatory intervention (e.g., price controls).  However, our 
research suggests that increases in drug spending may yield further increases in life expectancy.  
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INTRODUCTION 
 
  Auster et al. [1] were the first economists to study the production function for health.  
Since then, many similar analyses have been conducted using data from the United States or 
from multiple countries [2-22].  Several of these [3,6-8,11,13,20,21] have used aggregate data 
from the member countries of the Organization for Economic Cooperation and Development 
(OECD).  Given the large percentage of gross domestic product (GDP) expended on health 
among more developed nations (e.g., 12.9% in the US, 9.3% in Canada, and 9.3% in France in 
1999), one may reasonably infer that these countries collectively place a high priority on the 
health status of their populations.  Therefore, for informed policy purposes, it is extremely 
important that work on the population health production function be ongoing using the latest data 
available and the latest sound econometric methods. 
It has long been known that there is a strong positive correlation between average income 
and life expectancy [23].  Many studies of the production function for health have found that 
wealth, typically measured using per capita GDP, has a negative influence on mortality rates and 
a positive influence on life expectancy at various ages [3,6,9,17,20,21].  Most studies [1-
3,8,9,14,17,19,20,21] have found that the consumption of medical care has no statistically 
significant effect on measures of a population’s health.  The evidence pertaining to the effect of 
lifestyle factors, such as the consumption of tobacco products and alcohol, is more equivocal 
[3,14,20,21,24].  Few studies [9,13,15,16,20,21] have directly or indirectly dealt with the effect 
of pharmaceuticals on mortality or life expectancy.  Though many of these analyses have been 
flawed, the consensus among them is that pharmaceutical consumption has a positive impact on 
health.   
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In the last few years, a number of important, albeit expensive, new pharmaceutical agents 
have been brought into the marketplace [25,26].  Based on existing research, one would expect 
these to have a positive impact on a nation’s stock of health.  In order to investigate this 
important issue, we used more recent data than have been used in previous health production 
function studies, better measures of the variables involved, and improved econometric modeling 
techniques.  We also provide a new and original discussion of the major issues involved when 
using ecological data to study the production function for health.   Accordingly, the first section 
of this paper discusses our methodology.  In a following section, we discuss the results we 
obtained, including the effects of lifestyle factors, wealth, non-pharmaceutical health care 
consumption, and pharmaceutical consumption on the health stock.  We conclude with 





Data were taken from the OECD Health Data 2000 database.  OECD Health Data 2000 is 
an interactive database that contains aggregate data on the health care systems of 29 of the 30 
countries that are currently members of the OECD.  The database includes over 1,200 indicators 
spanning the period 1960 to 1999, with official data up to 1998 and selected estimates for 1999.  
In particular, the data set includes various measures of health status (morbidity and mortality), 
health care resources and utilization, health expenditures and financing, as well as information 
relating to population demographics, non-medical determinants of health (alcohol and tobacco 
consumption), and economic references (GDP and monetary conversion rates).  
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  We chose to work with the OECD Health Data for two reasons.  First, these data 
provided us with a readily identifiable population for the purpose of statistical inference.  That is, 
the population of more developed countries.  One may further delimit this population to those 
countries dedicated to democratic and market economic principles; however, given that most 
developed nations are committed to such principles, we view this qualifier as being unnecessary.  
Second, the data set includes a large number of social, health, and economic indicators, which 
obviated the need to abstract data from multiple sources.   
One may question our decision to focus on more developed countries as opposed to less 
developed nations.  We recognize the importance of ascertaining the determinants of population 
health in developing countries.  However, the consumption of pharmaceuticals in developed 
countries is, in general, much greater than that in developing countries.  Given the availability 
and utilization of pharmaceuticals in more developed countries, we believe it to be important to 
understand their effects on population health relative to other potentially important factors (e.g., 
diet, education, wealth).  In addition, data regarding drug consumption in developing nations are 
limited, which precluded a detailed analysis of the effect of drug consumption on population 
health in these countries.   
Variable definitions and descriptive statistics are presented in Table 1.  The dependent 
variables included life expectancies for males and females at ages 40, 60, and 65.  Life 
expectancy data were missing for Ireland in 1997, and we substituted 1995 data for this country 
in our model.  We hypothesized that health care and lifestyle factors would have cumulative 
effects on health.  That is, the consumption of some factor over time by an individual would 
either have a positive or negative effect on that individual’s health.  While it is conceivable that 
the consumption of certain factors (e.g., alcohol, tobacco) by a mother would influence the health 
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of her offspring, this represents a different model from the one we were interested in estimating.  
Thus, we chose not to include life expectancy at birth as a dependent variable in our model.   
Under the presumption that health care and lifestyle factors would have cumulative 
effects, we chose to lag the explanatory variables by roughly 15 years.  The literature suggested 
that a lag of 20 years or more would be appropriate for alcohol and tobacco consumption [27-
30].  However, there was little empirical evidence regarding the appropriate lag length for 
indicators of health care consumption.  Missing data precluded us from lagging expenditure 
variables by more than 12 years or lifestyle variables by more than 17 years.  A full model of this 
type would typically require several lags for each independent variable.  Because of data and 
sample size limitations, we included only one lag per variable.  
We measured income using per capita GDP in 1985.  Pharmaceutical and other health 
care consumption were measured using the 1985 per capita expenditures for each country.  
PHARM was computed as total per capita expenditures on pharmaceuticals and other medical 
non-durables minus per capita expenditures on medical non-durables (when data for the latter 
were available).  Our measure of pharmaceutical consumption included expenditures for 
outpatient prescription and over-the-counter medications as well as pharmacists’ remuneration.  
HEALTH was computed by subtracting PHARM from total per capita expenditures on health 
care.  Total health care expenditures in 1985 were missing for Greece and were estimated by 
summing total current expenditures on health and total investments in medical facilities.  
The OECD Health Data database includes specific purchasing power parity (PPP) 
conversion factors for pharmaceutical and health care expenditures in addition to conventional 
GDP-based conversion factors.  Elsewhere, it has been shown that pharmaceutical expenditures 
converted to U.S. dollars using GDP PPP exchange rates underestimate actual pharmaceutical 
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expenditures outside the U.S. [20,21].  The OECD pharmaceutical PPP exchange rates yield 
results that are consistent with those obtained using more accurate conversion factors developed 
by Szuba [31] and others.  Unfortunately, the pharmaceutical- and health-specific exchange rates 
are available only for a limited number of years (i.e., 1980, 1985, 1990, 1993, and 1996).  Thus, 
their availability influenced the lag we used for measures of income and health care 
consumption.  Income and expenditure variables were converted into U.S. dollars by dividing by 
the appropriate 1985 PPP conversion factor.  
Alcohol consumption was measured in liters consumed per capita by persons age 15 or 
older in 1980.  We substituted 1983 data for Greece since data on alcohol consumption in 1980 
were missing for this country.  Smoking behavior was controlled for using grams of tobacco 
consumed per capita by persons age 15 or older in 1980.  Data on tobacco consumption in 1980 
were missing for Germany, Ireland, and Italy.  For these countries, 1979 data were used instead.  
Data on tobacco consumption were unavailable for Spain in any year.  For this country, we 
substituted the mean value for tobacco consumption in 1980 for the other countries included in 
our sample.   
We also sought to control for the effects of dietary factors.  As a measure of positive 
dietary intake, we included fruit and vegetable consumption in kilograms per capita in 1980.  
Frech and Miller had reported animal fat to be an important predictor of life expectancy.  The 
measure of fat consumption they used is no longer collected by the OECD and was not available 
in the Health Data 2000 database.  Therefore, we elected to use butter consumption in kilograms 
per capita in 1980 as an alternate measure of animal fat intake.  This included quantities of butter 
used in food preparations or mixed with other fats to obtain particular types of margarine or 
cooking fats.  Certain studies [20,21,24] have suggested that the relationship between fat intake 
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and life expectancy is parabolic (i.e., low levels of fat consumption yield increased life 
expectancy, whereas higher levels of consumption yield reduced life expectancy).  We could 
have specified a curvilinear relationship between life expectancy and butter consumption by 
including a second-order term for the latter in our model.  However, we chose to exclude the 
second-order term since collinearity with the first-order term led to instability in the model’s 
parameter estimates.  
Because of missing data, we restricted our analysis to 19 of the 30 OECD countries.  We 
excluded Switzerland from our sample due to the limited availability of pharmaceutical and 
health-specific PPP exchange rates as well as tobacco and alcohol consumption data.  We also 
excluded Turkey from our sample since it is relatively underdeveloped when compared with the 
other member countries of the OECD. 
 
Model Specification 
We elected to use a log-linear functional form in modeling the data.  There are several 
reasons for this.  First, it allowed us to interpret our parameter estimates as elasticities.  Second, 
it allowed for diminishing marginal returns to the independent variables.  In a log-linear model, 
the elasticity is held constant, while the absolute value of the marginal effect for each 
explanatory variable is forced to fall at higher and higher values of the variable.  The continuous 
independent variables were centered prior to estimation to reduce multicollinearity.  A dummy 
variable for Spain was added to the model to control for the imputation of missing tobacco 
consumption data for this country. 
Initially, ordinary least squares (OLS) was used to estimate separate models for the six 
groupings   defined by age and sex.  The age-sex groupings were ages 40, 60, and 65  6 , , 1K = j
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for both males and females.  Country  19 , , 1K = i  was then the unit of observation in the 
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Tests were performed using the OLS residuals to ascertain whether life expectancy data for the 
six strata could be pooled.  We performed a test to determine whether the intercept varied among 
the six age-sex categories followed by a test for homogeneity of regression or parallelism.  These 
tests are often ascribed to Chow [32]; however, they were described earlier in a number of other 
sources [33-36].  To maintain an overall two-tailed alpha level of 0.05, the first test was 
performed with an alpha of 0.025, while the second was performed with an alpha of 0.05.  As 
would be expected, there was a significant difference among the six age-sex categories in the 
intercept term  .  However, the other parameters did not appear to 
vary significantly among the strata 
, 06 . 053 , 7 ( 107 , 5 < = p F
( ) 33 . 0 = p .   
Conventional tests for poolability assume spherical disturbances [37, p. 53].  In the 
presence of non-spherical disturbances, these tests are not robust.  For example, when estimating 
an error components model, they may exhibit a high frequency of Type I error when the variance 
components are large.  According to Baltagi [37], conventional tests for poolability should only 
be used after the disturbances have been transformed so that they are spherical.  Baltagi describes 
a method for transforming the disturbances that follows from the work of Roy [38] and Zellner 
[39].  Using the methods described by Baltagi [37, pp. 53-55], we performed the Roy-Zellner 
analogs of the intercept and parallelism tests.  These allowed for a one-way error components 
model in which country was treated as a random effect.  The data were transformed using 
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consistent estimates of the covariance matrices for the restricted and unrestricted models; thus, 
the test statistics followed an approximate F distribution.  The results were similar to those 
described in the preceding paragraph.  While there was a significant difference among the six 
age-sex categories in the intercept term ( , the parameter vectors 
(excluding the intercept) did not vary significantly among the strata ( .   
) 0001 . 0 , 16 . 709 , 1 ˆ
107 , 5 < = p F
ˆ F ) 19 . 0 , 29 . 1 60 , 40 = = p
Given the preceding results, we decided to pool life expectancy data for the six age-sex 
categories, adding dummy variables for age and sex to the model to control for differences in the 
intercept term.  We chose to estimate a mixed model that treated country as a random effect.  
Residual maximum likelihood (REML) was used to estimate the model, and the White estimator 
[40] was used to adjust for potential heteroscedasticity.  A sequential modeling approach was 
used to identify significant interactions between the dummy variables for age and sex and the 
other independent variables.  All terms that were significant at the  10 . 0 = p  level were included 
in the final model.  Equation (2) depicts the final model specification, where the  are fixed 
effects, the   are random country effects from a   distribution, and the 
s ' β
ij i u ) , 0 (
2
u N σ ε  are 
independently identically distributed errors (at the level of age-sex category within country) from 
a   distribution and are independent of the  .  ) , 0 (
2
ε σ N i u
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A number of tests were performed to assess the model’s goodness of fit.  The Shapiro-
Wilk test [41] was used to evaluate the normality of the error distribution.  Multicollinearity was 
assessed using Belsley’s condition index [42].  Ramsey’s regression specification error test 
(RESET test) [43] was used to test for omitted variables and/or incorrect functional form.  We 
added second- through fourth-order polynomials of the fitted values to the model and tested their 
joint significance.  The Breusch-Pagan Lagrange multiplier test [44] and Hausman test [45] were 
performed to evaluate the efficiency and consistency, respectively, of the random effects model.  
Finally, a robust test for first-order serial correlation [46] was performed.  
All statistical analyses were performed using SAS Release 8.02 (SAS Institute, Inc., 
Cary, NC) and Stata 8.0 (Stata Corporation, College Station, TX). 
 
Analysis of Marginal Effects 
  We computed the marginal effect of pharmaceutical consumption on life expectancy at a 
given age in two ways.  First, as shown in equation (3), we calculated the average number of 
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Second, as shown in equation (4), we calculated the average number of years of life expectancy 
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In each case,  ,  , and   represent estimates of the parameters specified in equation (2).  
Given that we specified a log-linear functional form and included a main effect for GDP in 
equation (2), our use of the same estimates in equations (3) and (4) is valid. 
2 ˆ β 16 ˆ β 17 ˆ β
We were interested in testing the significance of the difference between the largest and 
smallest marginal effects within each age-sex category.  This necessitated generating an estimate 
of the variability associated with the difference.  The distribution of differences between the 
extreme values of an order statistic is unknown.  However, the bootstrap can be used to generate 
a confidence interval to summarize the uncertainty in a parameter estimate.  Carpenter et al. [47] 
discuss parametric and nonparametric residual bootstrap methods that can be used to derive 
confidence intervals for the parameter estimates of a mixed model.  These methods are 
implemented in the current version of MLwiN (Centre for Multilevel Modelling, Institute of 
Education, London, United Kingdom).  We applied Carpenter et al.’s methods to derive 95% 
confidence intervals for the difference between the smallest and largest marginal effects in four 
of the six age-sex categories (i.e., males and females at ages 60 and 65).  
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The parametric bootstrap proceeded as follows.  The parameters β ,  , and   were 
estimated by REML using the model specified in equation (2).  We simulated   for 
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We then refitted the model to the bootstrap data and calculated the marginal effect of 
pharmaceutical consumption on life expectancy for each country within a given age-sex 
category.  We then computed the difference between the smallest and largest marginal effects 
within each age-sex grouping.  The entire process was repeated many times to generate an 
empirical distribution of 10,000 estimates for each of the four marginal effect differences.  The 
95% confidence interval for each difference was derived using the bias-corrected and accelerated 
(BCa) method [48,49].  Jackknifing was employed to derive the acceleration term, which 
involved estimating the parameters specified in model (2) while excluding one country at a time. 
  While the parametric bootstrap can be useful, it does not free inference from the 
assumption that the residuals have a normal distribution.  Parametric bootstrap confidence 
intervals will not adequately reflect any non-normality in the data.  Ergo, we thought it 
worthwhile to apply the nonparametric bootstrap in addition to the parametric method.  Using 
REML, we obtained parameter estimates for model (2) from the data and calculated the 
residuals, { 6 , , 1 ; 19 , , 1 } ˆ K K = = j i ij ε  and { .  The latter were the empirical best linear unbiased 
predictors.  The two sets of residuals were centered and then rescaled using methods described 
by Carpenter et al. [47] to have variances equal to those estimated by model (2).  We then 
19 , , 1 } ˆ K = i i u
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sampled independently and with replacement from the two sets, obtaining two new sets 
 and { .  Using these, we calculated the bootstrap data from equation 
(5), refitted the model to the bootstrap data, and calculated the difference between the smallest 
and largest marginal effects within each age-sex category.  The process of sampling from the 
residuals and estimating differences between marginal effects was repeated 10,000 times.  
Ninety-five percent BCa confidence intervals were then computed for the differences. 
6 , , 1 ; 19 , , 1 } { K K = =
∗





Though not entirely arbitrary, we recognize that some researchers may not agree with the 
lag structure used in this research.  We also recognize that some may criticize our decision to 
exclude Switzerland or the monetary conversion rates we used.  Because of these concerns, we 
elected to perform sensitivity analyses around several of the assumptions made in our model.   
First, we evaluated the impact of excluding Spain on the base model estimates.  When 
excluding Spain, we also excluded the dummy variable for Spain and its associated interactions.  
Second, we evaluated the impact of using GDP PPP or market exchange rates instead of the 
OECD PPP exchange rates on the base model estimates.  While doing so, we also evaluated the 
impact of including Switzerland on our results.  Recall that the primary reason for Switzerland’s 
exclusion was the lack of OECD PPP exchange rates in 1985.  Third, we evaluated the effects of 
different lag structures on our results.  The measure of tobacco consumption we used in our base 
model was not available for all countries (e.g., Germany, Italy, the U.S.) after 1980.  Thus, when 
performing sensitivity analyses around the lag structure of our model, tobacco consumption was 
measured in expenditures (U.S. dollars) per capita.  Three scenarios were considered:  (1) 1985 
economic data (GDP, PHARM, HEALTH) and 1980 lifestyle data (ETOH, TOB, BUTTER, 
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VEG) to provide a comparison with our base model, (2) 1985 economic and lifestyle data, and 
(3) 1990 economic and lifestyle data.  In each of the three scenarios, Spain was included in the 
sample, Switzerland was excluded, and economic data were converted into U.S. dollars using 
OECD PPP exchange rates.     
 
RESULTS AND DISCUSSION 
Base Model  
In general, the model appeared to provide a good fit for the observed data.  The Breusch-
Pagan test rejected OLS in favor of random effects  , while the Hausman 
test failed to reject the null hypothesis that the individual effects were uncorrelated with the other 
regressors.  Thus, the random effects model appeared to be both efficient and consistent.  The 
combined residuals were normally distributed (
) 0001 . 0 , 05 . 90 (
2
1 < = p χ
) 35 . 0 , 38 . 0 = = p
) 44 . 0 = p
z
, 70 . 2
, and serial correlation did not 
appear to be a problem  .  Multicollinearity appeared to be much less of an 
issue in our model than in some previous research.  The condition index for our model was 9.44, 
which did not exceed the commonly accepted threshold of 20-30 [42,50].  Finally, the RESET 
test failed to reject the null hypothesis  , suggesting that the model’s 
functional form was correctly specified. 
) 47 . 0 , 53 . 0 (
2




Table 2 presents the results for our base model.  The first five independent variables 
following the CONSTANT are dummy variables.  As such, their coefficients cannot be directly 
interpreted as elasticities; they must be converted into “pseudo” elasticities using the formula 
 [51].  Thus, for example, the elasticity coefficient for MALE would be 
.  This elasticity would be interpreted as follows:  being male (i.e., 
a change in the dummy variable MALE from zero to one) is associated with a 12.4% reduction in 
1 − =
β e E
7183 . 2 = E 1236 . 0 1
1319 . 0 − = −
−
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life expectancy relative to being female.  As would be expected, both male sex and advanced age 
were associated with reduced life expectancy.  The elasticity for the interaction of MALE and 
AGE60 was –0.5412 (e.g.,  ).  Similarly, the elasticity 
for the interaction of MALE and AGE65 was –0.6303, which implies that the life expectancy of 
a male at age 65 is 63% lower than the life expectancy of a female at age 40. 
5412 . 0 1 7183 . 2
0667 . 0 5805 . 0 1319 . 0 − = − =
− − − E
 In the following four subsections of the paper, we discuss the base model’s results with 




We found evidence that lifestyle factors, such as the consumption of alcohol, tobacco, 
butter, and fruits and vegetables, have important effects on life expectancy after controlling for 
the effects of wealth and health care consumption.  Our findings are generally consistent with 
those of many clinical and epidemiological studies [52-62] that have reported such lifestyle 
factors to be important predictors of mortality.  
Though alcohol consumption did not have a statistically significant effect on female life 
expectancy, its effect on the life expectancy of males was both significant and negative.  Our 
results indicate that a doubling of alcohol consumption per capita would be associated with an 
approximate 3.3% decrease in male life expectancy.  This finding most likely reflects a 
difference in alcohol intake between males and females and is consistent with the findings of 
Frech and Miller [20,21] and Cochrane et al. [3].  Although moderate drinking (i.e., no more than 
one drink a day for most women and no more than two drinks a day for most men) has been 
associated with psychological [63] and cardiovascular [64-67] benefits, it also increases risks for 
hemmorhagic stroke [68], motor vehicle accidents [69], adverse medication reactions [70,71], 
   17
and certain types of cancer [72,73].  Further, various researchers have suggested that moderate 
drinking is not cardioprotective, arguing that higher mortality among abstainers results from 
including among them people who have stopped drinking due to ill health.  At the ecological 
level, it is likely that the small health benefits provided by moderate drinking are outweighed by 
the risks associated with alcohol consumption.         
As would be expected, tobacco consumption had a statistically significant negative effect 
on life expectancy.  Our results indicate that a doubling in tobacco consumption per capita would 
be associated with an approximate 10.2% reduction in population life expectancy.  This is 
consistent with the findings of Cochrane et al. [3] and Wolfe and Gabay [8].  Cochrane et al. also 
controlled for the effects of per capita GDP, alcohol consumption, and poor diet in their models; 
however, they did not account for the effect of pharmaceutical consumption.  Our results differ 
from those of Frech and Miller [20,21] who reported that smoking had no significant effect on 
life expectancy.  Frech and Miller’s estimate of the effect of smoking on life expectancy was 
imprecise due to the measure of smoking that was used.  In addition, our proxy for smoking has 
the advantage of being an intensity measure.  Similar to micro-level measures such as pack-years 
or the number of cigarettes consumed daily, the number of grams of tobacco consumed annually 
per capita better captures the dose-response effect of smoking on health than simple exposure 
measures like the percentage of the population that smokes. 
Our proxy for animal fat intake behaved much like the other lifestyle factors included in 
the model.  The parameter estimate for butter consumption per capita was statistically significant 
and carried a positive sign.  There are several possible explanations for the apparent effect of 
butter consumption on life expectancy.  First, it is possible that the positive effect was the result 
of vitamin fortification.  In many developed countries, milk products, such as butter and 
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margarine, are fortified with vitamins A and D.  It is conceivable that this would have a positive 
effect on a population’s health.  Second, one might hypothesize that the positive effect of butter 
consumption was due to the use of butter as a spread for vegetables.  Although we investigated 
this hypothesis by testing for an interaction between butter consumption and vegetable 
consumption, we found no evidence to support it.  Third, the positive effect of butter 
consumption could have been due to omitted variable bias.  Since we explicitly controlled for the 
effect of wealth, it seems unlikely that our measure of fat intake simply captured an omitted 
income effect (i.e., that people in wealthier countries consumed fattier diets).  
Our findings with respect to butter consumption are consistent with those of a number of 
other studies.  Wolfe and Gabay [8] studied the relationship between negative changes in 
lifestyle and health status in a sample of OECD countries.  Although negative changes in 
lifestyle were associated with declines in health status, butter consumption was negatively 
related to the former, suggesting a positive association with health status.  Gage and O’Connor 
[24] reported that increases in the dietary contribution of fats relative to proteins were associated 
with increased life expectancy.  However, the effect was moderated by diet quality such that in 
the presence of a high-quality diet, the effect of a high fat-to-protein ratio on life expectancy was 
reversed.  Frech and Miller [20,21] also reported a curvilinear relationship between life 
expectancy and dietary fat intake such that low levels of consumption had a strong positive effect 
on life expectancy, while higher levels of consumption were associated with reduced life 
expectancy.  We chose to exclude a second-order term for butter consumption from our model 
due to extreme multicollinearity.  When adding the square of the logarithm of BUTTER to our 
model, the estimate for the first-order term was still positive and significant; however, the 
estimate for the second-order term bore a positive sign and was not statistically significant. 
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Other researchers have failed to detect an independent association between dietary fat 
intake and life expectancy or mortality.  Hertz et al. [14] used exploratory stepwise regression 
methods to estimate the effects of dietary and other factors on life expectancy at birth in 44 
countries.  Total fat calorie consumption and the proportion of fat calorie consumption not 
explained by total calorie consumption were included as regressors in the final model.  However, 
parameter estimates for these variables were not statistically significant.  Similarly, Cochrane et 
al. [3] found that total calorie, protein, and fat consumption contributed little in explaining 
mortality when controlling for per capita income.  More recent studies have suggested that the 
effect of dietary fat intake on mortality is confounded by age and pre-existing risk for heart 
disease.  A consensus among researchers has not yet been reached as to whether the consumption 
of saturated fats above recommended levels by individuals who are not already at high risk for 
heart disease increases the likelihood of untimely death [74-77]. 
Finally, as expected, per capita fruit and vegetable consumption had a statistically 
significant positive effect on life expectancy.  The effect of fruit and vegetable consumption was 
larger for males than for females and was larger for life expectancy at age 65 than at age 40.  As 
with alcohol consumption, these findings likely reflect differences in intake among groups.  In 
many developed countries, fruit and vegetable consumption appears to increase with increasing 
age among adults [78-82].  Further, although women tend to report eating fruits and vegetables 
with greater frequency than men, actual intake tends to be higher for the latter when more 
objective measures (e.g., average number of grams consumed daily) are used [80].  Since we 
measured intake using the number of kilograms consumed annually, it is not surprising that the 
effect of fruit and vegetable consumption on life expectancy was greater for males than females.   
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Wealth Effects  
 
  Per capita GDP was found to be an important predictor of life expectancy at ages 60 and 
65.  The marginal effect appeared to increase with increasing age, with elasticities of 0.03 for life 
expectancy at age 60 and 0.05 for life expectancy at age 65 (Table 2).  Based on these estimates, 
doubling per capita GDP would have the effect of increasing life expectancy at age 65 by 
roughly 5.5%.  In terms of remaining years of life, a 65-year-old male could expect to see his 
remaining life expectancy increase from an average of 15.4 years to 16.2 years.  Similarly, a 65-
year-old female could expect her life expectancy to increase from an average of 19 years to 20 
years.  These effects are consistent with the observation that economic development over the past 
several decades has led to increasing life expectancy.  Our results correspond to those of Frech 
and Miller [20,21], though our estimate for the effect of per capita GDP on life expectancy at age 
60 is somewhat smaller than theirs.   
Several studies [5,12,14] have found wealth to be unassociated with mortality or life 
expectancy after controlling for other explanatory variables.  Hadley [5] investigated the 
relationship between Medicare expenditures and mortality rates using 1980 U.S. Census data.  
Average family income was not associated with reduced mortality.  However, the investigator 
failed to use a functional form in his models that would account for a log-linear relationship 
between the two variables.  In addition, the results of this study are not directly comparable with 
our own since Hadley limited his analysis to elderly Medicare beneficiaries.  Using a sample of 
22 developing countries, Anand and Ravallion [12] reported that when controlling for a measure 
of poverty, the relationship between per capita GDP and life expectancy was not statistically 
significant.  There is a growing body of evidence [9,12,83-91] that the unequal distribution of 
income within a country is more important than mean or median income when predicting health, 
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particularly in developed countries.  We tested the validity of the relative income hypothesis in a 
subset of the 19 OECD countries included in our sample.  Using 1994 estimates for economic 
references and 1997 estimates for indices of health status, we observed that per capita GDP was 
more strongly associated with life expectancy at all ages than the percentage of the population 
earning less than 50% of median income.  This finding is consistent with recent evidence 
suggesting that data aggregation may reduce the correlation between health status and relative 
income [92].  While it may have been appropriate for us to include a measure of poverty or 
income inequality (such as the Gini coefficient) in our models, the limited availability of these 
data prevented us from doing so.   
At least two studies [1,11] have reported the independent effect of income on health to be 
negative.  Zweifel and Ferrari [11] derived a parameter estimate of -0.88 for 1970 per capita 
GDP when estimating life expectancy at ages 40 and 65 in 1980.  The results of this study are not 
directly comparable with our own since Zweifel and Ferrari specified a functional form for their 
model that did not account for nonlinear relationships among the variables.  Auster et al. [1] 
reported a positive association between income and mortality while controlling for the effects of 
medical care and education.  Their findings with respect to income differ from those of Cochrane 
et al. [3].  The latter also controlled for education and the consumption of medical care but 
reported that per capita gross national product was negatively associated with mortality.  
Anand and Ravallion [12] have argued that the positive effect of wealth on life 
expectancy reported by many researchers may be due to omitted variable bias.  Income does not 
contribute directly to health but acts through other factors such as education, housing, and food 
intake [22].  Data for school expectancy are available for only a few countries in the OECD 
Health Data database.  In addition, the data set includes no measures of the availability of 
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adequate housing.  We believe that GDP provided a good proxy for the effects of these agents in 
our investigation.  Still, as the OECD Health Data are updated and more data become available, 
it may be possible to model the specific effects of these factors.  
 
 
Non-Pharmaceutical Health Care Consumption Effects 
 
  As shown in Table 2, the consumption of health care other than pharmaceuticals had no 
discernable effect on life expectancy.  The parameter estimate for non-drug health care was 
positive though not statistically significant.  Other studies [1-3,8,9,14,17,19,20,21] have also 
reported health care consumption to be unrelated to life expectancy or mortality rates, although 
most of these did not make the distinction between drug and non-drug health care.  Frech and 
Miller [20,21] reported that the consumption of medical care other than pharmaceuticals had no 
significant effect on life expectancy at ages 40 and 60, though their parameter estimates were 
negative in sign.  The results of a study conducted by Wnuk-Lipinski and Illsley [10], though 
mixed, suggest the absence of a strong relationship between health system indicators (e.g., 
number of physicians, nurses, hospital beds) and mortality rates.   
A relatively small number of studies [4-6,11,12,18,22] have reported the effect of 
medical care on health to be positive.  None of these distinguished between drug and non-drug 
health care.  The results of some studies suggest that certain subpopulations may benefit from 
medical care services.  Based on the work of Hadley [4,5], the elderly would appear to be 
included among these.  Also, Bidani and Ravallion [18] found that differences in public health 
spending tend to matter more to the poor than to others.  While Zweifel and Ferrari [11] reported 
a positive association between life expectancy and lagged health care expenditures, differences 
in specification between their model and ours limit the comparability of parameter estimates.  In 
   23
a recent study, Evans et al. [22] used a fixed-effects translog model to estimate the effects of per 
capita health expenditures and years of schooling on average life expectancy in 191 
industrialized and developing countries.  In addition to failing to account for the independent 
effect of pharmaceuticals, the researchers excluded other potentially relevant variables (e.g., 
tobacco and alcohol consumption) from their model.   
  Our findings suggest that developed countries lie on the upper portion of the health care 
consumption curve where marginal rates of return are negligible.  However, the results may also 
be explained by what Zweifel and Ferrari [11] have called the Sisyphus syndrome.  The 
allocation of medical resources to health should promote increased life expectancy, but as 
longevity increases so do outlays on medical care.  At advanced ages, there is a strong demand 
for private, and especially public, health care services.  Given limited data for public 
expenditures, we did not make the distinction between private and public health care 
consumption in our study.   
 
 
 Pharmaceutical Consumption Effects 
 
Pharmaceutical consumption had a positive effect on life expectancy (Table 2).  As with 
per capita GDP, the elasticities for pharmaceutical consumption increased with increasing age.  
Doubling either the proportion of GDP allocated to pharmaceuticals or expenditures on 
pharmaceuticals per capita would increase life expectancy at ages 60 and 65 by 2.8% and 3.1%, 
respectively.  Increasing pharmaceutical consumption twofold, a typical 65-year-old male could 
expect to see his remaining life expectancy increase from 15.4 years to 15.9 years.  Similarly, a 
65-year-old female could expect her life expectancy to increase from 19 years to 19.6 years.  
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Our findings are consistent with those of Frech and Miller [20,21], Lichtenberg [15,16], 
and others who have found that pharmaceutical consumption is associated with increased life 
expectancy, reduced mortality rates, and improved outcomes.  Our results differ from those of 
Babazono and Hillman [13] who reported that per capita pharmaceutical expenditures have no 
effect on male or female life expectancy.  As noted by other researchers [20], this study has 
several flaws.  In particular, pharmaceutical expenditures were converted to U.S. dollars using 
GDP PPP exchange rates.  In addition, stepwise regression methods were used, which can lead to 
misleading statistical inferences as well as potentially biased estimates [50,51]. 
Table 3 presents the marginal effects of drug consumption on total population life 
expectancy at ages 60 and 65 for males and females.  The first four columns in the table report 
the marginal effects of pharmaceutical consumption in additional days of life expected in 1997 
per additional U.S. dollar spent on pharmaceuticals in 1985.  Countries with large per capita 
expenditures for pharmaceuticals in 1985 would stand to gain the least from marginal increases 
in drug consumption, whereas countries with small per capita drug expenditures in 1985 would 
realize the greatest life expectancy benefits.  For example, a $1 per capita increase in drug 
spending in France would have the smallest effect.  Average life expectancy at age 60 would be 
increased by 0.55 days for males and 0.69 days for females.  Likewise, a $1 per capita increase in 
drug spending in France would be associated with an increase in life expectancy at age 65 of 
0.50 days for males and 0.64 days for females.  On the other hand, an increase in drug spending 
would have the greatest effect in Ireland, where average life expectancy at age 60 would be 
increased by 2.62 days for males and 3.23 days for females.  Similarly, a $1 per capita increase 
in drug spending in Ireland would be associated with an increased life expectancy of 2.29 days 
for males and 2.91 days for females.  These findings are not surprising considering that countries 
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like Ireland and Canada have relatively low per capita pharmaceutical expenditures, while per 
capita drug spending is much higher in countries like France and Italy.   
The estimated confidence intervals indicate that significant differences exist among the 
marginal effects in each age-sex category.  Since the confidence intervals were derived from the 
empirical distributions of marginal effect differences, an alternative approach for evaluating 
significance would be to define a minimum meaningful difference between marginal effects and 
observe whether or not this is included in a given interval.  For example, we could say with 95% 
confidence that the maximum difference between marginal effects in each age-sex category is 
greater than 0.25 days of life expectancy gained in 1997 per U.S. dollar spent on pharmaceuticals 
in 1985.  For each age-sex category, the nonparametric and parametric bootstrap methods 
yielded similar confidence limits, providing further evidence that our data met the assumptions 
of the random effects model. 
The second four columns in Table 3 depict the marginal effects of pharmaceutical 
consumption in additional years of life expected in 1997 per additional 1% of GDP share spent 
on pharmaceuticals in 1985.  Countries that allocated a relatively small percentage of GDP to 
pharmaceuticals in 1985 (e.g., Austria, Canada, Denmark, the Netherlands) would stand to gain 
the most in life expectancy by marginally increasing their drug consumption.  Conversely, 
countries that spent a relatively large proportion of their GDP on pharmaceuticals in 1985 (e.g., 
France, Greece, Portugal, Italy) would stand to gain the least.  In Canada, where roughly 0.89% 
of GDP was spent on pharmaceuticals in 1985, a 1% increase in drug spending would yield an 
increase in life expectancy at age 65 of 0.61 years for males and 0.76 years for females. 
Conversely, a 1% increase in GDP share spent on pharmaceuticals in France, where 3.1% of 
GDP was allocated to drugs in 1985, would yield an increase in average life expectancy at age 65 
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of only about a fifth of a year for either sex.  The bootstrap confidence intervals suggest that 
significant differences exist among the marginal effects in each age-sex category.  As in the 
preceding case, the parametric and nonparametric methods yielded similar confidence limits. 
  Using the metric of days of life expectancy gained per capita dollar spent on 
pharmaceuticals, it appears that the U.S. would fare about as well as the “average” country in our 
sample.  In the U.S., an additional per capita dollar spent on drugs in 1985 would yield an 
increase in life expectancy at age 65 in 1997 of 1.25 days for males and 1.51 days for females.  
The average increase in life expectancy at age 65 would be 1.25 days for males and 1.55 days for 
females. Conversely, it appears that the U.S. would fare better than many other countries by 
increasing the proportion of GDP spent on pharmaceuticals.  In 1985, roughly 0.9% of GDP was 
allocated to pharmaceuticals in the U.S.  A 1% increase in GDP spending on drugs in the U.S. 
would yield an increase in life expectancy at age 65 of 0.58 years for males and 0.70 years for 
females.  The average increase in life expectancy at age 65 would be 0.39 years for males and 
0.49 for females.  Thus, the important metric for the U.S. appears to be the proportion of GDP 
allocated toward pharmaceuticals. 
 
Sensitivity Analyses 
Table 4 shows the sensitivity of parameter estimates for economic variables to the 
exclusion of Spain, the inclusion of Switzerland, the use of alternative exchange rates, and 
changes in the model lag structure.  Table 5 shows the sensitivity of parameter estimates for 
lifestyle variables to these same factors.  Excluding Spain from the sample had no appreciable 
effect on any of our findings.  When using the GDP PPP exchange rates, the estimate for the 
main effect of GDP was larger than that in our base model, while the estimates for 
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pharmaceutical and non-drug health care consumption were somewhat attenuated.  However, the 
significance of the parameter estimates was not greatly changed.  When using market exchange 
rates, there were no significant GDP effects, and estimates for the interaction of GDP with age 
were negligible.  In addition, the estimated effects for pharmaceutical and non-drug health care 
consumption were reduced in magnitude.  When using either of these alternative exchange rates, 
the addition of Switzerland to the sample did not yield large changes in the parameter estimates 
or their statistical significance.  Based on these findings, our interpretation is that the GDP PPP 
and market exchange rates are inferior to the OECD PPP exchange rates used in our base model. 
  Because there is no published research on lag structure in this area of health economics, 
and because it is problematic to deduce lag structure on an a priori basis, we also varied the lag 
structure in the base model to ascertain whether this would influence our results.  As shown at 
the bottom of Table 4 and Table 5, we varied the economic data for the years 1985 and 1990 and 
the lifestyle data for the years 1980, 1985, and 1990.  In the model in which economic data were 
measured in 1985, lifestyle data were measured in 1980, and tobacco consumption was measured 
in U.S. dollars per capita, our estimate for the effect of tobacco consumption was -0.07.  This 
was somewhat smaller than the estimate for tobacco consumption in our base model.  The 
estimate for the main effect of GDP was larger than that in our base model though still not 
statistically significant.  Parameter estimates for interactions involving GDP and age were 
attenuated, while estimates for interactions involving pharmaceutical consumption and age were 
increased in magnitude.  Further, the estimate for the main effect of vegetable consumption was 
reduced, while estimates for the interaction of vegetable consumption with age were somewhat 
larger than those in our base model.   Aside from these differences, the results were fairly 
consistent with those presented in Table 2. 
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Increasing recency in the measurement of explanatory variables was associated with 
reductions in both the magnitude and statistical significance of parameter estimates for lifestyle 
factors.  This finding indicates that our choice of a cumulative effects model was appropriate for 
tobacco, alcohol, vegetable, and butter consumption.  Parameter estimates for interactions 
involving pharmaceutical consumption and age did not change appreciably as we moved closer 
to the year in which life expectancy was measured.  However, the main effect for pharmaceutical 
consumption was both positive and significant when 1990 economic data were used.  This 
suggests that a contemporaneous effects model might have provided an even better fit for the 
pharmaceutical expenditures data.  One explanation for this finding is that a broader range of 
more effective drugs is available today than was available in previous decades.  Interestingly, the 
parameter estimates for interactions involving GDP and age grew in magnitude as we moved 
closer to the year in which life expectancy was measured.  It appears that variance in life 
expectancy that had formerly been explained by the lifestyle variables was absorbed by GDP.  
 
Issues Related to Data Aggregation 
It would have been highly desirable to use individual-level data in our analyses.  Of 
course, individual-level data were not available for the full set of 19 countries included in our 
sample.  There are several problems associated with the use of aggregate data, including small 
sample size, a limited range of variation in variables, and heightened sensitivity to outliers 
compared to individual-level data.  Our use of aggregated data for each country theoretically led 
to a loss of efficiency.  In addition, when using aggregate data, heteroscedasticity may result if 
each grouping does not contain the same number of observations.  However, aggregation can 
cancel out errors in measurement or misspecifications of micro-relationships.   
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There are several specific issues related to our use of aggregate data that should be 
addressed.  First, we did not explicitly account for population migration between countries.  
There are hardly any data on the mobility of populations between OECD nations, and no data of 
this type are available in the OECD Health Data 2000 database.  Even if we did have an indicator 
of population migration, we suspect that its marginal effect would be small.  During the years 
analyzed, it is reasonable to presume that the population growth within each country occurred 
mainly as a result of increases in the birth rate as opposed to migration between countries.  
Second, no adjustment was made for underlying differences between individuals in factors that 
might influence health status (e.g., chronic diseases).  To the extent that these factors were 
distributed similarly in each country, we feel that an analysis using mean life expectancy data 
was valid.  Third, our use of aggregate data masked differences between countries in the relative 
price and availability of pharmaceuticals.  We attempted to adjust for cross-national price 
differences using the OECD’s pharmaceutical PPP exchange rates.  While this method was 
imperfect, it is widely recognized that there is no single, correct measure of international price 
differences for pharmaceuticals [93].  Sensitivity analyses were performed to evaluate the 




  In a sample of more developed countries, we found that drug consumption, as measured 
by per capita pharmaceutical expenditures, has a positive effect on population life expectancy at 
various ages.  The marginal effect of pharmaceutical consumption is somewhat smaller than has 
been previously reported and appears to decline with increasing age.  The consumption of health 
care other than pharmaceuticals was found to have a negligible effect on life expectancy.  We 
   30
observed that wealth, as measured by per capita GDP, has a large, positive effect on life 
expectancy.  In addition, a variety of lifestyle factors were found to have important effects in 
producing health after controlling for the effects of wealth and pharmaceutical consumption.  
Our results are broadly consistent with those of Frech and Miller [20,21] who conducted a 
similar analysis in a sample of 21 OECD countries. 
Upwardly spiraling pharmaceutical expenditures have given rise to concern among policy 
makers and consumers in the U.S. and other developed countries.  However, our research 
suggests that increases in pharmaceutical spending may yield significant health benefits in many 
countries, particularly with respect to life expectancy.  In order to have a positive impact on 
health, increased expenditures must be associated with an increased volume or outlays on novel 
therapeutic agents that demonstrate greater efficacy than existing medications.  Increases in 
expenditures due to increases in the prices of existing medications or on new market entries that 
provide no clinical advantage over less-costly existing therapies will provide no additional health 
benefits.   
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Table 1.  Variable definitions and descriptive statistics. 
 
CONTINUOUS VARIABLES 
Variable            Definition Mean SD Minimum Maximum
LEM40  Number of years of life expectancy for males at age 40, 1997  36.55  1.00  34.70  38.10 
LEM60  Number of years of life expectancy for males at age 60, 1997  19.17  0.82  17.40  20.10 
LEM65  Number of years of life expectancy for males at age 65, 1997  15.46  0.76  13.70  16.30 
LEF40  Number of years of life expectancy for females at age 40, 1997  41.71  1.11  39.50  43.50 
LEF60  Number of years of life expectancy for females at age 60, 1997  23.38  0.98  21.50  25.20 
LEF65  Number of years of life expectancy for females at age 65, 1997  19.19  0.91  17.40  20.80 
GDP  Gross domestic product per capita, 1985 U.S. dollars   11,719.11  2,751.13  6,105.00  16,976.00 
PHARM  Pharmaceutical expenditures per capita, 1985 U.S. dollars  171.26  72.20  73.21  400.34 
HEALTH  Health expenditures (not including pharmaceuticals) per capita, 1985 U.S. 
dollars 
1,100.26       
       
       
      
      
448.04 309.71 1,960.05
ETOH  Liters of ethyl alcohol consumed annually per capita by persons age 15 or 
older, 1980 
11.99 3.82 5.30 20.60
TOB  Grams of tobacco consumed annually per capita by persons age 15 or older, 
1980 
2,727.33 530.18 1,492.00 3,588.00
BUTTER  Kilograms of butter consumed annually per capita, 1980  6.01  4.05  0.50  13.90 
VEG  Kilograms of fruits and vegetables consumed annually per capita, 1980 
 
187.01  66.20  70.90  362.20 
DISCRETE VARIABLES 
Variable  Definition
MALE  Dummy variable taking on value of 1 if dependent variable was life expectancy for males and 0 otherwise 
AGE60  Dummy variable taking on value of 1 if dependent variable was life expectancy at age 60 and 0 otherwise 
AGE65  Dummy variable taking on value of 1 if dependent variable was life expectancy at age 65 and 0 otherwise 
SPAIN  Dummy variable taking on value of 1 if country was Spain and 0 otherwise 
 
Note:  Descriptive statistics apply to the sample of 19 countries.  Independent variables included in the sensitivity analysis of model lag structure 
were measured in 1980, 1985, or 1990.  
SD = standard deviation. 
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AGE65 × ln(PHARM)  0.0308
a 
(0.0079) 
MALE × ln(VEG)  0.0301
a 
(0.0123) 


















Sample size:  114 observations. 
Note:  Robust standard errors given in parentheses. 
a  Significantly different from 0, p < 0.05, two-tailed. 
b  Significantly different from 0, p < 0.10, two-tailed. 







Table 3.  Marginal effect of pharmaceutical consumption on life expectancy at various ages. 
 
  Days per U.S. Dollar  Years per 1% GDP Share 
 Males Females Males Females 
Country  Age 60  Age 65  Age 60  Age 65  Age 60  Age 65  Age 60  Age 65 
Australia                  1.42 1.28 1.72 1.57 0.52 0.47 0.63 0.57
Austria                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
               
                 
                 
                 
                 
                 
          
1.85 1.66 2.27 2.06 0.62 0.56 0.76 0.69
Belgium 0.89 0.80 1.12 1.02 0.30 0.27 0.38 0.34
Canada 1.71 1.55 2.07 1.91 0.68 0.61 0.82 0.76
Denmark 1.64 1.47 1.98 1.81 0.60 0.54 0.73 0.67
Finland 1.54 1.37 1.91 1.73 0.50 0.45 0.62 0.56
France 0.55 0.50 0.69 0.64 0.20 0.18 0.25 0.23
Germany 1.08 0.97 1.32 1.20 0.39 0.35 0.49 0.44
Greece 1.26 1.13 1.45 1.31 0.25 0.22 0.28 0.26
Ireland 2.62 2.29 3.23 2.91 0.54 0.47 0.66 0.60
Italy 0.80 0.71 0.99 0.91 0.26 0.23 0.32 0.29
Netherlands 1.92 1.70 2.40 2.18 0.62 0.55 0.77 0.70
New  Zealand
 
1.42 1.28 1.70 1.57 0.44 0.39 0.52 0.48
Norway 1.41 1.25 1.72 1.57 0.53 0.47 0.65 0.59
Portugal 1.39 1.24 1.71 1.53 0.23 0.21 0.29 0.26
Spain 1.28 1.15 1.58 1.44 0.28 0.25 0.35 0.32
Sweden 1.31 1.17 1.57 1.44 0.47 0.42 0.56 0.51
U.K. 1.00 0.88 1.20 1.09 0.31 0.27 0.37 0.34
U.S. 1.38 1.25 1.64 1.51 0.64 0.58 0.76 0.70
Average (SD)  1.39 (0.46)  1.25 (0.40)  1.70 (0.57)  1.55 (0.51)  0.44 (0.16)  0.39 (0.14)  0.54 (0.19)  0.49 (0.18) 
Difference
a                 
          
2.07
 
1.79 2.54 2.27 0.48 0.44 0.57 0.53
95%  CI  (LL, UL)
  Nonparametric  0.30, 4.59  0.33, 3.70  0.36, 5.64  0.42, 4.70  0.07, 1.07  0.08, 0.90  0.08, 1.27  0.10, 1.09 
  Parametric  0.29, 4.51  0.28, 3.63  0.35, 5.55  0.36, 4.61  0.07, 1.05  0.07, 0.88  0.08, 1.25  0.08, 1.07 
 
SD = standard deviation; CI = confidence interval; LL = lower limit; UL = upper limit. 




Table 4.  Economic variables:  sensitivity of regression results to changes in the measurement of model parameters. 
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   1990 Economic Data / 






















































































Note:  Robust standard errors given in parentheses. 
a  Significantly different from 0, p < 0.05, two-tailed. 




 Table 5.  Lifestyle variables:  sensitivity of regression results to changes in the measurement of model parameters. 
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   1990 Economic Data / 
































































































Note:  Robust standard errors given in parentheses.   
a  Significantly different from 0, p < 0.05, two-tailed. 
b  Significantly different from 0, p < 0.10, two-tailed.  
c  Tobacco consumption measured in U.S. dollars per capita. 